Almost 25 years after his father died of heart failure, Australian biomedical engineer Daniel Timms is trying to revolutionize cardiac care. Timms’ company BiVacor makes an artificial heart that, just like the real thing, can propel blood throughout the body. As part of an ongoing feasibility study, three U.S. patients this year received BiVacor hearts, which kept them alive long enough to wait for donor organs. That result is “remarkable,” Timms says, but his ambitions are even bigger. If short-term trials are successful, BiVacor will test whether its heart can work indefinitely, perhaps eliminating the need for live-organ transplants altogether. “This device didn’t exist for my family,” Timms says, but it could be life-changing—and life-saving—for others.
More Must-Reads from TIME
- Where Trump 2.0 Will Differ From 1.0
- How Elon Musk Became a Kingmaker
- The Power—And Limits—of Peer Support
- The 100 Must-Read Books of 2024
- Column: If Optimism Feels Ridiculous Now, Try Hope
- The Future of Climate Action Is Trade Policy
- FX’s Say Nothing Is the Must-Watch Political Thriller of 2024
- Merle Bombardieri Is Helping People Make the Baby Decision
Write to Jamie Ducharme at jamie.ducharme@time.com